Latest Insider Transactions at Cullinan Oncology, Inc. (CGEM)
This section provides a real-time view of insider transactions for Cullinan Oncology, Inc. (CGEM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cullinan Oncology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cullinan Oncology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 13
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
119,508
-4.16%
|
$1,195,080
$10.22 P/Share
|
|
May 13
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
109,900
+2.71%
|
$989,100
$9.13 P/Share
|
|
May 12
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
264,072
-15.31%
|
$2,376,648
$9.25 P/Share
|
|
May 12
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,000,000
+13.9%
|
$9,000,000
$9.06 P/Share
|
|
Apr 01
2022
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
276,000
+4.22%
|
$2,760,000
$10.75 P/Share
|
|
Feb 11
2022
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+48.54%
|
-
|
|
Feb 11
2022
|
Corrine Savill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,500
+7.3%
|
-
|
|
Feb 11
2022
|
Leigh Zawel Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+31.77%
|
-
|
|
Feb 11
2022
|
Patrick Baeuerle Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Feb 11
2022
|
Raymond T Keane Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+48.26%
|
-
|
|
Feb 11
2022
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,500
+35.66%
|
-
|
|
Jan 11
2022
|
Vision Scs F2 > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,187,734
-40.78%
|
-
|
|
Oct 18
2021
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-5.07%
|
$88,000
$22.37 P/Share
|
|
Oct 18
2021
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+12.94%
|
$16,000
$4.3 P/Share
|
|
Oct 15
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
19,574
-34.43%
|
$489,350
$25.0 P/Share
|
|
Oct 15
2021
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,000
-78.05%
|
$200,000
$25.0 P/Share
|
|
Oct 15
2021
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+43.84%
|
$32,000
$4.3 P/Share
|
|
Oct 07
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
1,079
-1.86%
|
$26,975
$25.0 P/Share
|
|
Sep 20
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
7,468
-11.42%
|
$186,700
$25.16 P/Share
|
|
Sep 20
2021
|
Jennifer Michaelson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.63%
|
$96,000
$24.77 P/Share
|
|
Sep 20
2021
|
Jennifer Michaelson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+12.94%
|
$16,000
$4.3 P/Share
|
|
Sep 16
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
3,124
-0.04%
|
$90,596
$29.06 P/Share
|
|
Sep 16
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
432
-0.18%
|
$12,528
$29.06 P/Share
|
|
Sep 16
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,124
-0.04%
|
$90,596
$29.06 P/Share
|
|
Sep 15
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
6,425
-0.08%
|
$186,325
$29.16 P/Share
|
|
Sep 15
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
888
-0.36%
|
$25,752
$29.16 P/Share
|
|
Sep 15
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
6,425
-0.08%
|
$186,325
$29.16 P/Share
|
|
Sep 14
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
7,106
-0.09%
|
$206,074
$29.17 P/Share
|
|
Sep 14
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
982
-0.4%
|
$28,478
$29.17 P/Share
|
|
Sep 14
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
7,106
-0.09%
|
$206,074
$29.17 P/Share
|
|
Sep 13
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
3,595
-0.05%
|
$104,255
$29.1 P/Share
|
|
Sep 13
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
497
-0.2%
|
$14,413
$29.1 P/Share
|
|
Sep 13
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,595
-0.05%
|
$104,255
$29.1 P/Share
|
|
Sep 10
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
5,931
-0.08%
|
$171,999
$29.04 P/Share
|
|
Sep 10
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
820
-0.33%
|
$23,780
$29.04 P/Share
|
|
Sep 10
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,931
-0.08%
|
$171,999
$29.04 P/Share
|
|
Sep 09
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
13,727
-0.18%
|
$398,083
$29.35 P/Share
|
|
Sep 09
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,898
-0.76%
|
$55,042
$29.35 P/Share
|
|
Sep 09
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
13,727
-0.18%
|
$398,083
$29.35 P/Share
|
|
Sep 08
2021
|
Jeffrey Trigilio Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-56.34%
|
$420,000
$28.34 P/Share
|
|
Sep 08
2021
|
Jeffrey Trigilio Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+46.51%
|
$60,000
$4.3 P/Share
|
|
Sep 08
2021
|
Patrick Baeuerle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
11,000
-100.0%
|
$308,000
$28.45 P/Share
|
|
Sep 08
2021
|
Patrick Baeuerle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+50.0%
|
$44,000
$4.3 P/Share
|
|
Sep 08
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
10,842
-0.14%
|
$314,418
$29.11 P/Share
|
|
Sep 08
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
1,499
-0.6%
|
$43,471
$29.11 P/Share
|
|
Sep 08
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
10,842
-0.14%
|
$314,418
$29.11 P/Share
|
|
Sep 07
2021
|
Leigh Zawel Officer |
SELL
Open market or private sale
|
Direct |
28,118
-30.07%
|
$787,304
$28.95 P/Share
|
|
Sep 07
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Indirect |
25,067
-0.32%
|
$726,943
$29.04 P/Share
|
|
Sep 07
2021
|
Ansbert Gadicke Director |
SELL
Open market or private sale
|
Direct |
3,465
-1.36%
|
$100,485
$29.04 P/Share
|
|
Sep 07
2021
|
Ubs Oncology Impact Fund L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
25,067
-0.32%
|
$726,943
$29.04 P/Share
|